Related Experiment Video
Updated: Dec 28, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Congenital factor VII deficiency in Iraqi children (Single Centre Experience)
Ali Ahmed Khudhair1, Afrah Abdul-Mahdi Salih2, Ausama Jamal Kadhum3
1Dr. Ali Ahmed Khudhair, C.A.B.P, FICMS (PED). Department of Pediatrics, Children Welfare Teaching Hospital, Baghdad, Iraq.
Insights
Factor VII (FVII) deficiency, a rare bleeding disorder, presents with variable symptoms not always linked to FVII levels. Most patients in this study showed a normal outcome, highlighting the diverse clinical spectrum of FVII deficiency.
Area of Science:
- Hematology
- Rare bleeding disorders
- Coagulation disorders
Background:
- Factor VII (FVII) deficiency is a rare autosomal recessive coagulation disorder.
- Estimated prevalence of 1:500,000, affecting all age groups.
- Characterized by variable clinical manifestations and hemostatic values.
Purpose of the Study:
- To describe demographic parameters of FVII deficiency.
- To detail symptomatology and hemostatic values.
- To evaluate the outcome of FVII deficiency.
Main Methods:
- Retrospective descriptive study.
- Seven-year data collection (August 2008 - August 2015).
- Review of patient files for diagnosis, interventions, complications, and follow-up.
Main Results:
- Twenty-four patients (17 female, 7 male) included; most diagnosed under one year.
- Severe phenotype common; epistaxis most frequent symptom (41.7%).
- Clinical presentation variability noted, with 75% having a normal outcome.
Conclusions:
- Clinical manifestations of FVII deficiency are diverse.
- FVII levels do not always correlate with disease phenotype.
- Variable presentation and outcomes observed in congenital FVII deficiency.
Background And Objective:
Factor VII (FVII) deficiency is probably one of the most common of the rare autosomal recessive coagulation disorders, with an estimated prevalence of l: 500000. All age groups can be affected with FVII deficiency. This study aimed to describe the demographic parameters, symptomatology, hemostatic values and the outcome of FVII deficiency.
Methods:
This is a retrospective descriptive study of patients with congenital FVII deficiency over a period of seven years from (August 2008 to August 2015). The data were collected by reviewing the files for each patient diagnosed with FVII deficiency. Surgical interventions, complications and follow up visits were recorded.
Results:
Twenty-four patients were included in this study, 17 females and seven males, below one year was the most common age at presentation. More than half of patients (58.3%) were diagnosed within six months of symptoms onset. The majority of patients had severe phenotype. The most common symptom was epitaxis (41.7%). Five out of 10 patients with FVII level < 1% have either mild to moderate phenotype of the disease without complications; while six out of 14 patients with FVII > 1% had at least one episode of severe bleeding. Three patients had hepatitis C; all were treated by blood products before the introduction of recombinant FVII in Iraq. The outcome of most patients (75%) was normal without complications at time of study.
Conclusion:
Clinical manifestations of FVII deficiency are variable and they are not necessarily correlated to the FVII level.
More Related Videos
Related Concept Videos
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis III: Interprofessional Care
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

